Skip to main content
SpringerLink
Log in

The Post-NSAID Era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Traditionally, clinicians have relied heavily on the use of NSAIDs to treat the pain of osteoarthritis, as numerous studies have proven these agents effective. However, controversy has arisen regarding their use as first-line therapy, due to increasing awareness of their cardiovascular risks. One of these agents, rofecoxib, was withdrawn from the market in 2004 due to these concerns. Since that time, numerous studies have illustrated that many of the NSAIDs, both the selective cyclooxygenase-2 inhibitors and the traditional nonselective agents, may confer similar risks of cardiovascular toxicity. Although these agents may still be useful in many patients, concerns over side effects have begun to limit their use, and patients and clinicians are reaching for alternate agents. This review highlights the evidence behind the effectiveness of other, non-NSAID pharmacologic options in the treatment of pain and inflammation in osteoarthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Lin EH, Tang L, Katen W, et al.: Arthritis pain and disability: response to collaborative depression care. Gen Hosp Psychiatry 2006, 28:482–486.

    Article  PubMed  Google Scholar 

  2. Bjordal JM, Ljunggren AE, Klovning A, Slordal L: Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomized placebo controlled trials. BMJ 2004, 329:1317.

    Article  PubMed  CAS  Google Scholar 

  3. Mitchell JA, Warner TD: COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 2006, 5:75–86.

    Article  PubMed  CAS  Google Scholar 

  4. Grosser T, Fries S, FitzGerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006, 116:4–15.

    Article  PubMed  CAS  Google Scholar 

  5. Patrono C: The PGH-synthase system and isozyme-selective inhibition. J Cardiovasc Pharmacol 2006, 47(Suppl 1):S1–S6.

    Article  PubMed  CAS  Google Scholar 

  6. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520–1528.

    Article  PubMed  CAS  Google Scholar 

  7. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286:954–959.

    Article  PubMed  CAS  Google Scholar 

  8. Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247–1255.

    Article  PubMed  CAS  Google Scholar 

  9. Singh G, Fort JG, Goldstein JL, et al.: Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 2006, 119:255–266.

    Article  PubMed  CAS  Google Scholar 

  10. Arber N, Eagle CJ, Spicak J, et al.: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355:885–895.

    Article  PubMed  CAS  Google Scholar 

  11. Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071–1080.

    Article  PubMed  CAS  Google Scholar 

  12. Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092–1102.

    Article  PubMed  CAS  Google Scholar 

  13. Solomon DH, Avorn J, Stürmer T, et al.: Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006, 54:1378–1389.

    Article  PubMed  CAS  Google Scholar 

  14. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al.: NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006, 27:1657–1663.

    Article  PubMed  Google Scholar 

  15. Singh G, Mithal A, Triadafilopoulos G: Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class. Ann Rheum Dis 2005, 64(Suppl III):85.

    Google Scholar 

  16. Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005, 330:1366.

    Article  PubMed  CAS  Google Scholar 

  17. Graham DJ, Campen D, Hui R, et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475–481.

    PubMed  CAS  Google Scholar 

  18. Solomon DH, Schneeweiss S, Levin R, Avorn J: Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004, 44:140–145.

    Article  PubMed  CAS  Google Scholar 

  19. Solomon DH, Schneeweiss S, Glynn RJ, et al.: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004, 109:2068–2073.

    Article  PubMed  CAS  Google Scholar 

  20. Catella-Lawson F, Reilly MP, Kapoor SC, et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345:1809–1817.

    Article  PubMed  CAS  Google Scholar 

  21. Gaziano JM, Gibson CM: Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection. Am J Cardiol 2006, 97:23–29.

    Article  PubMed  Google Scholar 

  22. Krum H, Aw TJ, Liew D, Haas S: Blood pressure effects of COX-2 inhibitors. J Cardiovasc Pharmacol 2006, 47(Suppl 1):S43–S48.

    Article  PubMed  CAS  Google Scholar 

  23. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000, 43:1905–1915.

  24. Bradley JD, Brandt KD, Katz BP, et al.: Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991, 325:87–91.

    PubMed  CAS  Google Scholar 

  25. Pincus T, Koch GG, Sokka T, et al.: A randomized, doubleblind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001, 44:1587–1598.

    Article  PubMed  CAS  Google Scholar 

  26. Case JP, Baliunas AJ, Block JA: Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis; a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003, 163:169–178.

    Article  PubMed  CAS  Google Scholar 

  27. Pincus T, Koch G, Lei J, et al.: Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES); two randomized, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004, 63:931–939.

    Article  PubMed  CAS  Google Scholar 

  28. Towheed TE, Maxwell L, Judd MG, et al.: Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006, 1:CD004257.

  29. Curhan GC, Knight EL, Rosner B, et al.: Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 2004, 164:1519–1524.

    Article  PubMed  Google Scholar 

  30. Forman JP, Rimm EB, Curhan GC: Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007, 167:394–399.

    Article  PubMed  Google Scholar 

  31. Chan AT, Manson JE, Albert CM, et al.: Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006, 113:1578–1587.

    Article  PubMed  CAS  Google Scholar 

  32. Shipton AE: Tramadol—present and future. Anaesth Intensive Care 2000, 28:363–374.

    PubMed  CAS  Google Scholar 

  33. Cepeda MS, Camargo F, Zea C, Valencia L: Tramadol for osteoarthritis: a systematic review and meta-analysis. J Rheumatol 2007, 34:543–555.

    PubMed  CAS  Google Scholar 

  34. Markenson JA, Croft J, Zhang PG, Richards P: Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 2005, 21:524–535.

    Article  PubMed  Google Scholar 

  35. Langford R, McKenna F, Ratcliffe S, et al.: Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum 2006, 54:1829–1837.

    Article  PubMed  CAS  Google Scholar 

  36. Golub LM, McNamara TF, D’Angelo G, et al.: A non-antibacterial chemically modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987, 66:1310–1314.

    PubMed  CAS  Google Scholar 

  37. Cole AA, Chubinskaya S, Luchene LJ, et al.: Doxycycline disrupts chondrocyte differentiation and inhibits cartilage matrix degradation. Arthritis Rheum 1994, 37:1727–1734.

    Article  PubMed  CAS  Google Scholar 

  38. Yu LP Jr, Smith GN Jr, Brandt KD, et al.: Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992, 35:1150–1159.

    Article  PubMed  Google Scholar 

  39. Brandt KD, Mazzuca SA, Katz BP, et al.: Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005, 52:2015–2025.

    Article  PubMed  CAS  Google Scholar 

  40. Little CB, Meeker CT, Golub SB, et al.: Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J Clin Invest 2007, 117:1627–1636.

    Article  PubMed  CAS  Google Scholar 

  41. Goldring SR, Goldring MB: The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 2004, 427(Suppl):S27–S36.

    Article  PubMed  Google Scholar 

  42. Pelletier JP, Yaron M, Haraoi B, et al.: Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. Arthritis Rheum 2000, 43:2339–2348.

    Article  PubMed  CAS  Google Scholar 

  43. Fidelix T, Soares B, Trevisani V: Diacerein for osteoarthritis. Cochrane Database Syst Rev 2005, 1:CD005117.

  44. Bellamy N, Campbell J, Robinson B, et al.: Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006, 2:CD005328.

  45. Papachristou G, Anagnostou S, Katsorhis T: The effect of intraarticular hydrocortisone injection on the articular cartilage of rabbits. Acta Orthop Scan Suppl 1997, 275:132–134.

    Google Scholar 

  46. Bellamy N, Campbell J, Robinson B, et al.: Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006, 2:CD005321.

  47. Wang CT, Lin YT, Chiang BL, et al.: High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage 2006, 14:1237–1247.

    Article  PubMed  Google Scholar 

  48. Chevalier X, Giraudeau B, Conrozier T, et al.: Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005, 32:1317–1323.

    PubMed  CAS  Google Scholar 

  49. Deal CL, Schnitzer TJ, Lipstein E, et al.: Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 1991, 13:383–395.

    PubMed  CAS  Google Scholar 

  50. Reinharth D: Capsaicin cream unpopular with patients. Arch Intern Med 2005, 165:702.

    Article  PubMed  Google Scholar 

  51. Lin J, Zhang W, Jones A, Doherty M: Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomized controlled trials. BMJ 2004, 329:324.

    Article  PubMed  CAS  Google Scholar 

  52. Gammaitoni AR, Galer BS, Onawola R, et al.: Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale. Curr Med Res Opin 2004, 20(Suppl 2):S13–S19.

    Article  PubMed  CAS  Google Scholar 

  53. Burch F, Codding C, Patel N, et al.: Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthritis Cartilage 2004, 12:253–255.

    Article  PubMed  CAS  Google Scholar 

  54. Ernst E: Complementary or alternative therapies for osteoarthritis. Nat Clin Pract Rheumatol 2006, 2:74–80.

    Article  PubMed  Google Scholar 

  55. Theodosakis J, Adderly B, Fox B: The Arthritis Cure. New York: St. Martin’s Press; 1997.

    Google Scholar 

  56. Clegg DO, Reda DJ, Harris CL, et al.: Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Eng J Med 2006, 354:795–808.

    Article  CAS  Google Scholar 

  57. Herrero-Beaumont G, Ivorra JAR, del Carmen Trabado M, et al.: Glucosamine sulfate in the treatment of knee osteoarthritis symptoms. Arthritis Rheum 2007, 56:555–567.

    Article  PubMed  CAS  Google Scholar 

  58. McAlindon TE, LaValley MP, Glin JP, Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000, 283:1469–1475.

    Article  PubMed  CAS  Google Scholar 

  59. Towheed TE, Maxwell L, Anastassiades TP, et al.: Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005, 2:CD002946.

  60. Biggee BA, Blinn CM, Nuite M, et al.: Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. Ann Rheum Dis 2007, 66:260–262.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY, 10021, USA

    Carla R. Scanzello

Authors
  1. Carla R. Scanzello
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neal K. Moskowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Allan Gibofsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carla R. Scanzello.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scanzello, C.R., Moskowitz, N.K. & Gibofsky, A. The Post-NSAID Era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Curr Rheumatol Rep 10, 49–56 (2008). https://doi.org/10.1007/s11926-008-0009-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-008-0009-6

Keywords

Search

Navigation